Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression.
Kramer
M S
MS
Merck Research Laboratories, Merck and Co., West Point, PA 19422, USA. mark_kramer@merck.com
D000818:Animals; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists; D013373:Substance P / Q000037:antagonists & inhibitors*
D064729:Neurokinin-1 Receptor Antagonists; D013373:Substance P